Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.
Study Type
OBSERVATIONAL
Enrollment
34
Imperial care Dialysis Center
Lynwood, California, United States
Barnett Research and Communications Medical Group
Torrance, California, United States
Number of Study-emergent Bone-related Adverse Events (AEs)
Time frame: 5 years
Number of Study-emergent Deaths
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Western new England Renal & Transplant Associates
Springfield, Massachusetts, United States
Mercy Medical Center
Canton, Ohio, United States
Hypertension & Nephrology, Inc.
Providence, Rhode Island, United States
Nephrology Associates, PC
Nashville, Tennessee, United States
University of Vermont
Burlington, Vermont, United States
Nephrology Associates, PC
Richmond, Virginia, United States
Unnamed facility
Bad König, Hesse, Germany
KfH Zentrum
Aachen, Germany
...and 9 more locations